Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov;37(6):573-584.
doi: 10.1007/s00292-016-0247-8.

[Categorization of uterine cervix tumors : What's new in the 2014 WHO classification]

[Article in German]
Affiliations
Review

[Categorization of uterine cervix tumors : What's new in the 2014 WHO classification]

[Article in German]
S F Lax et al. Pathologe. 2016 Nov.

Abstract

In the 2014 WHO classification, squamous cell precursor lesions are classified as low-grade and high-grade intraepithelial lesions. LSIL corresponds to CIN1, HSIL includes CIN2 and CIN3. Only adenocarcinoma in situ (AIS) is accepted as precursor of adenocarcinoma and includes the stratified mucin-producing intraepithelial lesion (SMILE). Although relatively rare, adenocarcinoma and squamous cell carcinoma can be mixed with a poorly differentiated neuroendocrine carcinoma. Most cervical adenocarcinomas are low grade and of endocervical type. Mucinous carcinomas show marked intra- and extracellular mucin production. Almost all squamous cell carcinomas, the vast majority of adenocarcinomas, and many rare carcinoma types are HPV related. For low grade endocervical adenocarcinomas, the pattern-based classification according to Silva should be reported. Neuroendocrine tumors are rare and are classified into low-grade and high-grade, whereby the term carcinoid is still used.

Keywords: Adenocarcinoma; Carcinoma in situ; Human papilloma virus; Immunohistochemistry; Squamous intraepithelial lesions of the cervix.

PubMed Disclaimer

References

    1. Am J Surg Pathol. 2000 Oct;24(10):1414-9 - PubMed
    1. Pathologe. 2016 Nov;37(6):549-556 - PubMed
    1. Lab Invest. 2003 Jan;83(1):35-45 - PubMed
    1. Int J Cancer. 2011 Mar 15;128(6):1354-62 - PubMed
    1. Clin Cancer Res. 2012 Aug 1;18(15):4154-62 - PubMed

MeSH terms